Kwame Frimpong is a notable inventor based in Indianapolis, IN (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compounds for treating various medical conditions. With a total of 2 patents, his work is recognized for its potential impact on healthcare.

Latest Patents

Frimpong's latest patents include groundbreaking inventions such as IL-17A inhibitors. This invention provides certain difluorocyclohexyl-imidazopyridazinyl-imidazolidinone compounds of formula II as IL-17A inhibitors, along with pharmaceutical compositions and methods for treating symptoms of psoriasis, rheumatoid arthritis, or multiple sclerosis. Another significant patent involves 1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, which are formulated for use as AICARFT inhibitors in cancer treatment.

Career Highlights

Kwame Frimpong is currently employed at Eli Lilly and Company, where he continues to advance his research and development efforts. His work at this prestigious pharmaceutical company has allowed him to focus on innovative solutions that address critical health issues.

Collaborations

Frimpong collaborates with esteemed colleagues, including David Andrew Coates and William Glen Holloway. These partnerships enhance the research environment and contribute to the success of their projects.

Conclusion

Kwame Frimpong's contributions to pharmaceutical research exemplify the spirit of innovation in the medical field. His patents and ongoing work at Eli Lilly and Company highlight his commitment to improving patient outcomes through scientific advancements.

Profile summary based on public USPTO records.